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Introduction
Chlorodibenzo-p-dioxins, especially 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD), are
among the most toxic compounds known.
These compounds are found as contaminants
of technical chlorophenols and their deriv-
atives. A variety of pathologic condition
have been associated with the injestion of
products containing chlorodibenzo-p-dioxins.
Toxic fat, the cause of chick edema dis-
ease (1, 2) and a variety of pathologic man-
ifestations in monkeys (3), has been found
to contain chlorodibenzo-p-dioxins, among
which is TCDD (4, 5). TCDD has been im-
plicated in a variety of other toxicoses, in-
cluding outbreaks of chloracne in chemical
workers (6), hepatonecrosis in rabbits (6),
and hepatonecrosis and thymic atrophy in
rats (7). However, only in the studies in
which monkeys were fed toxic fat (3) and
in which rats were given TCDD orally (7,
8) were substantial clinical pathologic
analyses performed.
Toxic fat caused in the monkeys, among
other lesions, anemia, leukopenia and hypo-
proteinemia. The hypoproteinemia was pri-
marily due to decreased serum albumin
concentration. The blood urea nitrogen
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(BUN), serum bilirubin, cholesterol, sod-
ium and potassium concentrations, and the
prothrombin times were not altered (3).
Rats given 10 mg TCDD/kg body weight
had, among the other lesions, increased ac-
tivities of serum glutamic-oxaloacetic trans-
aminase (SGOT), serum glutamic-pyruvate
transaminase (SGPT), lactic dehydro-
genase (LDH), and hydroxybuturate dehy-
drogenase as well as decreased arylesterase
and cholinesterase activities. In addition, the
rats had decreased serum glucose, sodium,
and protein concentrations, and increased
serum urea, lipid and bilirubin concentra-
tions, hemoconcentration, and neutrophilia.
Serum cholesterol, potassium and chloride
concentrations and aldolase and alkaline
phosphatase (AP) activities were not al-
tered (7, 8).
Because the clinical pathologic and path-
ologic changes found in these and other
studies suggest that the most profound ef-
fect of chlorodibenzo-p-dioxins are on the
liver and various hematopoietic organs, we
decided to determine the sequential clinical
pathologic changes which might occur in
rats given different doses of TCDD over a
period of time. These methods might also
determine which functions are the most
sensitive to TCDD. In addition, hematologic
.studies were conducted as an adjuvant to
studies of immunologic effects of TCDD in
September 1973 IIIguinea pigs (9) and in mice in which the
effects of TCDD on o6genesis are being de-
termined (J. McLachlan, personal commu-
nication).
Materials and Methods
Animals
Female CD rats weighing 150-175 g were
given, orally, 0.1, 1.0, or 10.0 Ixg TCDD/kg
daily for 30 days. Blood for the clinical
pathologic studies was obtained from the
heart 3, 6, 10, 13, 17, 24, and 31 days after
the TCDD dosing commenced.
Blood was obtained from the retroorbital
sinus for hematologic studies 1, 3, and 5
weeks after 8-week-old female CD-1 mice
were given oral doses of TCDD of 1.0, 10.0,
or 50 ,g/kg.
Female Hartley strain guinea pigs weigh-
ing about 250 g received oral weekly doses
of 0.008, 0.04, 0.2, or 1.0 ug TCDD/kg for
8 weeks. The 1.0 jug TCDD/kg group be-
came moribund between 3 and 5 weeks.
Half the animals were injected with tetanus
toxoid (group A) and half with killed My-
cobacterium tuberculosis (group B)
in order to determine the effects of TCDD
on humoral and cell-mediated immune re-
sponses. The details of these experimental
procedures can be found elsewhere in this
issue (9). The highest dose guinea pigs
when moribund and the other animals at
8 weeks were bled from the heart for hema-
tologic analysis.
Procedures
Routine methods were used for hemato-
logic determinations. Platelet counts were de-
termined in counting chambers (Uno-
pette, Becton, Dickinson and Company,
Rutherford, N. J.), fibrinogen by a heat-
denaturation method (10); urea nitrogen
was determined by a urease method (Boeh-
ringer-Mannhein Co., New York, N. Y.),
cholesterol by a ferric chloride method
(Hyland, Costa Mesa, California), serum
proteins by the biuret technioue (11), glu-
cose by an o-toluidine method (Hyland,
Costa Mesa, California), creatiniine by an
alkaline picrate method (12), bilirubin by
a sulfanilic acid-caffeine-sodium benzoate
method (Boehringer-Mannheim Co., New
York, N. Y.), sodium and potassium by flame
photometry, and chloride by coulometric
titration. The serum enzymes, alkaline
phosphatase (AP), lactic dehydrogenase
(LDH), glutamic-oxaloacetic transaminase
(SGOT), and glutamic pyruvate transamin-
ase (SGPT) were determined by kinetic
methods by use of commercially available
kits (Sigma Chemical Co., St. Louis, Mis-
souri) in a recording spectrophotometer.
Analysis of Data
Statistical analysis for differences between
groups was done by Dunnett's test (13).
Determination of a dose response was done
by Jonckheere's method (14). The 5%
level was selected as the value where vari-
ables would be considered significantly dif-
ferent.
Results
Rats
Enzymic alterations in the TCDD-treated
rats consisted of increased SGPT activity
in the high-dose (10.0/ug TCDD/kg-day)
rats at days 17, 24, and 31 (Fig. 1), and
increased SGOT activity at days 13, 17, 24,
and 31 in the high-dose rats as well as
days 13 and 17 in the middle-dose (1.0 14g
TCDD/kg-day) rats (Fig. 2). LDH was
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FIGURE 1. SGPT activity in rats treated with 0.1,
1.0, or 10.0 ltg TCDD/kg-day. High-dose rats had
increased SGPT activity at days 17 (P <0.01) and
24 (P <0.05). The asterisk (*) indicates a single
observation. All other points are the means of
three or four observations.
Environmental Health Perspectives 112elevated only on day 24 in the high-dose
rats, and AP was not altered at any time.
Serum cholesterol was increased on days
10, 17, 24, and 31 in the high-dose rats and
day 24 in the middle-dose animals. Significant
dose-response elevations for cholesterol con-
centrations were also found on days 17 and
24 (Fig. 3). Blood glucose concentration
decreased with time in all the treated
groups. At day 10, glucose concentrations
in all treated animals were significantly
decreased and on days 24 and 31 in the
high and middle dose animals it was de-
creased. Significant dose-response blood
glucose decreases were found at days 10, 17,
and 24 (Fig. 4). Total serum protein fluctu-
ated with the treatment. On days 24 and 31,
the high-dose rats had decreased protein
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FIGURE 2. SGOT activity in rats treated with 0.1,
1.0, or 10.0, g TCDD/kg-day. Significant increases
were found in the high-dose rats on days 13, 17,
and 24 (P <0.01) and in the middle-dose rats on
days 13 and 17 (P <0.05). Significant dose re-
sponses were found on days 13 (P <0.01), 17
(P <0.01), and 31 (P <0.05). The asterisk (*) in-
dicates a single observation. All other values are
means of three or four observations.
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FIGURE 3. Serum cholesterol concentration in rats
given 0.1, 1.0 or 10.0 Ag TCDD/kg-day. Signifi-
cant elevations occurred on days 10 (P <0.05) and
24 (P <0.01) in the high-dose rats and on day 24
(P <0.05) in the middle-dose rats. Significant
(P <0.05) dose responses were found on days 17
and 24. The asterisk (*) indicates a single ob-
servations. All other values are the means of three
or four observations.
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FIGURE 4. Blood glucose concentration in rats treated
with 0.1, 1.0, or 10.0 ,ug TCDD/kg-day. Significant
(P <0.05) decreases occurred on day 10 in the low-
dose rats and the middle-dose rats. Highly signifi-
cant (P <0.01) decreases occurred in the middle-
dose rats on day 24 and in the high-dose rats on
days 10 and 17. Significant dose responses occurred
on days 10 (P <0.01), 17 (P <0.05 and 24
(P <0.01). The asterisk (*) indicates a single ob-
servation. All other values are the means of three
or four observations.
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FIGURE 5. Serum protein concentration in rats
treated with 0.1, 1.0, or 10.0 ,ug TCDD/kg-day.
Significant (P <0.05) increased concentrations oc-
curred in the middle-dose rats on days 31 and de-
creased concentration in the high-dose rats on day
24. The asterisk (*) indicates a single observation.
All other values are the means of three or four
observations.
September 1973
0 Control
A 0.1lug/kg t
o l.OALg/kg
A IO.O.ALg/kg
/00 \. -i A
_ I \~~~~~~~~~~~~~~.
_ j .#~~~* _~~~~~~~~~~~~~~~-A
_. -a-- -O-
*Control
AO.I)±g/kg 0 * *- .-
01.Oig/kg
AIO.Ojug/kg
140 H
120-
100
80
8
co
E
S
a,
U,
*Control A
AO.Ilug/kg /,d\---
.I1O0,g/kg / *10.F9/k , ,/;,/
o- v \~~~~~~~~
\.' _.
113concentration while at day 31 it was in-
creased in the middle-dose rats (Fig. 5).
In addition, serum bilirubin concentrations
were increased in the high-dose animals on
days 17, 24, and 31 (Table 1). No signifi-
cant changes were found for serum creatin-
ine, sodium, potassium, chloride, fibrinogen,
and BUN concentrations.
Table 1. Bilirubin concentration in TCDD-treated
rats.'
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Bilirubin concentration, mg/100 ml serum
Time,
days Control 1.0jug/kg-day 10.0 jAg/kg-day
13 0.41 ± 0.10 0.83 ± 0.28 b
17 0.25 ± 0.08 0.22 ± 0.09 1.94 ± 0.42 e
24 0.64 ± 0.51 0.44 ± 0.15 5.62 ± 1.07
31 0.52 ± 0.15 0.40 ± 0.09 2.16 d
"Mean ± 1 S.D.
b P <0.05.
cP <0.01.
d Single value.
FIGURE 7. Hematocrit in rats given 0.1, 1.0, or 10.0
jAg TCDD/kg-day. Highly significant (P <0.01
increases occurred in the high-dose rats on days
17 and 24. All values are the means of three or
four observations.
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I Hematologic changes were confined to
hemoconcentration, as previously noted in
rats (7), in the high-dose animals on days
17 and 24 (Figs. 6-8), and to striking
thrombocytopenia in all the groups. After
only 3 days treatment, the high and mid-
dle-dose animals had depressed platelet
counts which remained depressed through-
out the study. In the low-dose rats (0.1 jug
TCDD/kg-day), platelets were decreased
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FIGURE 6. Erythrocyte count in rats given 0.1, 1.0,
or 10.0 jig TCDD/kg-day. Significant increases
occurred in the high-dose rats on days 17 and 24
(P <0.01). All values are the means of three or
four observations.
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FIGURE 8. Hemoglobin concentration in rats given
0.1, 1.0,' or 10.0 jig/kg-day. Highly significant
(P <0.01) increases occurred on days 17 and 24
in the high-dose rats. All values are the means of
three or four observations.
significantly only on day 17. Significant
dose response decreases in platelets occurred
throughout the study (Fig. 9). No signifi-
cant changes occurred in leukocyte counts
or differentials (in particular, lymphocytes)
in these rats.
Mice
Mice given a single oral dose of 1.0,
10.0, or 50.0 ug TCDD/kg had significantly
decreased leukocyte (Table 2) and lympho-
cyte counts (Table 3) after 1 week. After
3 weeks, none of the treatment groups had
significant differences from control mice;
however, a significant dose-response lympho-
cyte depression remained. The leukocyte de-
pression was on the borderline of being a
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FIGURE 9. Relative platelet counts in rats treated
with 0.1, 1.0, or 10.0 ,ug TCDD/kg-day. Significant
(P <0.05) decreases occurred in the low-dose rats
on day 17, the middle-dose rats on days 3, 10, and
31 and in the high-dose rats on day 24. Highly
significant (P <0.01) decreases occurred in the
middle-dose rats on day 24 and the high-dose rats
on days 10 and 17. Significant dose-responses oc-
curred on days 3 P <0.05), 10 (P <0.01), 17
(P <0.01), 24 (P <0.01, and 31 (P <0.05). The
mean numbers of platelets at day 3 in the control
rats were 1109 x 103/mm' blood. All values are
the means of three or four observations.
significant dose-response. After 5 weeks, no
TCDD effects were detected except that the
mice treated with 10 jug TCDD/kg had sig-
nificantly elevated erythrocyte counts (Ta-
ble 4). This difference is probably due to a
lack of variability in the parameter rather
than a real elevation and likely does not re-
flect an effect of TCDD.
Guinea Pigs
The TCDD-treated guinea pigs in the
tetanus toxoid-injected group (group A)
(9) had consistently lower leukocyte counts
than the controls, but only for the middle-
dose animals (0.04 jug TCDD/kg) was this
decrease significant (Table 5). The lympho-
cyte counts were significantly decreased
in all the TCDD-treated animals in this
group. A significant dose response oc-
curred for the leukocyte and lymphocyte
decreases also, but these effects simply re-
flect the depression observed at all three
TCDD treatment levels.
Table 2. Leukocyte counts in mice given a single oral dose of TCDD.
Leukocyte count X 10' per mm'
Controls 1 Ag/kg 10,ug/kg 50 Ag/kg
Dose
Week x SD x SD x SD x SD response a
1 12.05 2.58 8.35 b 1.72 8.78 b 0.74 6.08 0.90 P1 <0.01
3 8.07 2.50 6.53 0.65 5.43 0.91 6.10 2.29 P1 =0.052
5 8.70 3.67 8.23 3.82 7.30 1.49 7.27 3.95 P1 =0.222
aP1 =one-side P value.
bp (one-sided) <0.05.
c P (one-sided) <0.01.
Table 3. Lymphocyte counts in mice given a single oral dose of TCDD.
Lymphocyte count per mm'
Controls 1 Atg/kg 10,ug/kg 50 ,g/kg
Dose
Week x SD x SD x SD x SD response a
1 9233.0 1551.7 6276.5 b 1405.8 6443.5 b 1112.9 3752.2 b 378.6 P1 <0.01
3 6170.7 1872.1 5363.0 422.2 3788.3 839.8 4414.3 1764.6 P1 =0.037
5 6353.3 3261.2 6587.7 3482.6 5024.3 405.7 4864.0 2679.8 Pi =0.182
a P1 = one-sided P value.
b P (one-sided) <0.01.
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115Table 4. Erythrocyte counts X 106 in mice given a single oral dose of TCDD.
Erythrocyte count X 10' per mm'
Controls 1 ug/kg 10 ug/kg 50 ,ug/kg
Dose
Week x SD x SD x SD x SD response
1 7.28 0.320 7.30 0.141 6.90 0.356 7.33 0.479 NS -
3 7.63 0.115 7.57 0.306 7.43 0.058 7.33 0.252 NS a
5 7.53 0.058 7.73 0.153 7.80b 7.83 0.569 P2 = 0.045
a NS = not significant.
b P2 = two-sided P value.
Table 5. Leukocyte, lymphocyte, and neutrophil counts in group A guinea pigs treated
with TCDD for 8 weeks.
Count per mm'
Control 0.008 /Ag/kg-wk 0.04 ,gg/kg-wk 0.2,ug/kg-wk
Dose
Variable x SD x SD x SD x SD response
Leukocytes 6407.8 1878.0 5050.0 1161.7 4850.0 a 1237.6 4914.3 990.7 P = 0.022
Lymphocytes 4159.7 1465.3 2390.9 b 726.8 2872.6 a 1031.4 2591.7 a 459.3 P = 0.021
Neutrophils 1885.6 559.2 2286.5 1269.5 1668.7 466.6 2096.7 634.7 NS e
a P <0.05.
bP <0.01.
Table 6. Hematologic parameters for group B guinea pigs treated with TCDD for
8 weeks.
Control 0.008,ug/kg-wk 0.04,g/kg-wk 0.2 Ag/kg-wk Dose
x SD x SD z SD x SD response
Leukocytes per mm' 8840.0 4205.1 8230.0 a 2482.9 7260.0 1659.5 6140.08 2910.2 P <0.01
Lymphocytes per mm' 4270.5 2293.3 4229.1 1312.0 3717.5 1169.1 3628.2 2371.7 P = 0.024
Neutropil per mm' 3517.6 2127.6 3405.9 1204.4 3104.3 654.8 2179.3 a 718.7 P = 0.020
Platelets X 10-' 796.500 103.496 - 645.000 b 84.755
per mm'
Erythrocytes x 104 4.16 0.28 4.24 0.25 4.18 0.30 4.26 0.25 NS'
per mm'
Hemoglobin, 10.74. 0.57 11.00 0.40 11.29 0.57 10.59 0.66 NS
g/100 ml
Hematocrit, % 41.70 1.84 42.25 1.77 41.90 2.34 40.45 2.22 NS
a P <0.05.
b P <0.01.
e NS = not significant.
For Group B (Mycobacterium tubercu-
losis tuberculin-treated) (9) only the high-
est dose (0.2 ,g TCDD/kg) caused signifi-
cantly decreased leukocyte counts (Table
6). Neutrophil counts were also reduced in
these guinea pigs, but there was no treat-
ment versus control differences in lympho-
cyte counts. Significant dose-related de-
creases were found for leukocytes, neutro-
phils, and lymphocytes. In addition, the
guinea pigs treated with 0.2 4g TCDD/kg
also had lower platelet counts than the con-
trols (P< 0.01).
The leukocyte and lymphocyte counts of
the group A and group B control guinea
pigs did not differ significantly (Table 7).
However, the group B controls did have
higher neutrophil counts than the group B
controls (P< 0.05). When the group A con-
trol guinea pigs were compared with the
moribund 1.0 /g TCDD/kg guinea pigs, de-
creased lymphocyte and increased neutro-
Environmental Health Perspectives 116Table 7. Leukocyte counts of tetanus toxoid-treated (group A), Mycobacterium
tuberculosis tuberculin-treated (group B), and TCDD-treated guinea pigs.
Group A controls Group B controls 1.0 ,ug TCDD/kg-wk
Variable x SD x SD x SD
Leukocyte count per mm' 6407.8 1878.0 8840.0 4205.1 6800.0 4018.7
Lymphocyte count per mm' 4159.7 1465.3 4270.5 2293.3 1804.0 522.4
Neutrophil count per mm' 1885.6 559.2 2517.6b 2127.6 4686.4' 3534.7
P<0.01.
bP<0.05.
phil counts were found in the treated ani-
mals. However, this comparison may not be
valid because the TCDD-treated guinea pigs
were 3 to 5 weeks younger than the group
A controls and were in a moribund state in
addition to not having been injected with
tetanus toxoid. Hemoconcentration was also
present in these dying animals, there being
an average erythrocyte count of 5.1 x 106
per mm3 and a hematocrit of 48.9%o. Plate-
let counts were decreased as well.
Discussion
The clinical pathologic findings of this
and other studies (3, 7, 8) suggest that the
major sites of the toxic action of TCDD
and the chlorodibenzo-p-dioxins of toxic fat
are the hematopoietic system and the liver.
Mice and guinea pigs given TCDD and mon-
keys fed toxic fat (3) were leukopenic,
which in mice and guinea pigs is character-
ized by lymphopenia. In mice which re-
ceived a single dose of TCDD the lympho-
penia was reversed 5 weeks after TCDD
exposure. Perhaps the lymphopenia seen
in mice and guinea pigs is related to the
decreased cell-mediated immune response
observed in these two species after TCDD
exposure (9). It is interesting that lympho-
penia and cell-mediated immunosuppression
were not found in rats treated with TCDD.
Rats and guinea pigs were thrombocyto-
penic. The cause of this was not determined.
Examination of rat bone marrow in one
experiment did not reveal any differences
in numbers or morphology of megakaryo-
cytes following TCDD treatment (17), but
in another experiment in rats, spleen and
bone marrow megakaryocytes were degen-
erated and appeared to be reduced in num-
bers (15). Therefore, further work is in-
dicated to determine, perhaps by radioiso-
tope tagging, whether the lowered platelet
counts are due to decreased production or
increased distruction of platelets. Neverthe-
less, thrombocytopenia or defects in the
clotting mechanism (17) might have played
a role in the production of hemorrhages that
were occasionally seen in rats that died
(15).
Anemia was not found in these studies,
but it was seen in a previous study in mon-
keys fed toxic fat (3). That anemia was
accompanied by atrophic bone marrow and
normal serum bilirubin suggesting that the
anemia was aplastic or depression type
rather than hemolytic anemia.
We observed only terminal hemoconcen-
tration in rats and guinea pigs, similar
to that previously reported in rats given
TCDD (7). This is probably an effect of
terminal shock and dehydration rather than
increased erythrocyte production. Dehydra-
tion is further evidenced by the increased
serum protein concentrations found in the
middle-dose rats. However, hypoproteinemia
was observed in the high-dose rats probably
as a result of liver damage, and may have
contributed further to the hemoconcentra-
tion by decreasing the colloidal osmotic
pressure of the blood and allowing fluid to
accumulate in the tissues.
Liver damage in rats was evidenced by
increased SGOT and SGPT activity. The
increased SGOT activity might also be due
to, in part, myocardial necrosis (15). Hyper-
bilirubinemia, hypercholesterolemia, and hy-
poproteinemia (in the high-dose rats) are
September 1973 117probably other effects of the liver pathology.
Since increased cholesterol concentrations
have previously been seen in rats (18) and
rabbits (19) which have sustained hepato-
cellular damage from polychlorinated bi-
phenyls, perhaps metabolism of cholesterol
is altered in liver damage caused by these
chlorinated compounds. Hypoglycemia in
the TCDD-treated rats might have been due
to decreased food consumption (16), but
there might also be an effect on the glucon-
eogenic ability of the damaged liver. Al-
though clinical chemical parameters to as-
sess liver damage were not determined in
guinea pigs and mice, histopathologic evi-
dence suggests that hepatocellular damage
was minimal in these species (15).
It appears that hepatocellular necrosis is
the main toxic action of TCDD in rats but
with effects on platelets being important.
The clinical pathologic changes are consist-
ent with this hypothesis. Ultimately, hemo-
concentration due to shock and dehydra-
tion occurs as a terminal event in rats as
well as guinea pigs.
The lymphopenia observed in mice and
guinea pigs are consistent with the immu-
nosuppressive effects of TCDD in these
species (9). Pathologic studies suggest that
liver damage does not play a part in the
death of guinea pigs given high doses of
TCDD (15). However, in guinea pigs,
atrophy of the adrenal zona glomerulosa
(9, 15) suggests that electrolyte imbalance
might occur. Perhaps a study of serum elec-
trolyte and aldosterone concentrations in
guinea pigs given lethal doses of TCDD is
warranted.
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